Ipsen 17

a melanocortin 4 receptor antagonist; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Morbid Obesity 08/01/2014 - "Taken together, these results indicate that Ipsen 17 represents a candidate for the development of a targeted treatment of severe early-onset morbid obesity caused by a large subset of inherited mutations in the human MC4R gene. "
2.	Obesity 08/01/2014 - "As tested with 12 obesity-causing human MC4R variants including S58C, E61K, N62S, I69T, P78L, C84R, G98R, T162I, R165W, W174C, C271Y, and P299H, Ipsen 17 was found to be the most universal pharmacological chaperone of MC4R reported so far because it can completely rescue nearly all mutant receptors (except P299H) with the highest potency (an EC50 value of approximately 10(-8) M) and efficiency when compared with results for other tested pharmacological chaperones of MC4R including ML00253764, PBA, MTHP, PPPone, MPCI, DCPMP, and NBP described in the literature. "

1.	2- (2- (2- (5- bromo- 2- methoxyphenyl)ethyl)- 3- fluorophenyl)- 4,5- dihydro- 1H- imidazole